Table 2.

Meta-regression model results for objective response rate and grade 3–4 adverse events.

Objective Response Rate
Variable	Predicted Rate, % (95% CI)	Odds Ratio (95% CI)	P
Dosage
N1 +I3 Q3W	41.0 (31.9–50.8)	Reference
N3 + I1 Q3W	30.8 (21.8–41.4)	0.72 (0.39–1.30)	0.275
Other	31.5 (22.0–42.9)	0.92 (0.49–1.72)	0.786
Cancer Type
Lung Cancer	31.4 (21.7–43.2)	Reference
Melanoma	47.0 (38.2–56.0)	1.74 (0.90–3.35)	0.099
RCC	42.8 (31.6–54.8)	1.76 (0.86–3.62)	0.123
Other	24.8 (16.6–35.2)	1.21 (0.65–2.26)	0.541
Grade 3–4 Adverse Events
Variable	Predicted Incidence, (95% CI)	Odds Ratio (95% CI)	P
Dosage
N1 +I3 Q3W	55.9 (44.9–66.3)	Reference
N3 + I1 Q3W	31.3 (22.7–41.4)	0.52 (0.32-0.87)	0.012
Other	34.1 (27.4–41.5)	0.64 (0.38-1.08)	0.098
Cancer Type
Lung Cancer	31.9 (27.4–36.8)	Reference
Melanoma	55.6 (46.4–64.5)	2.23 (1.32–3.75)	0.003
RCC	48.4 (34.4–62.6)	2.31 (1.40–3.80)	0.001
Other	28.4 (20.9–37.2)	1.10 (0.70–1.73)	0.666

RCC, Renal cell carcinoma; CI, Confidence interval.